Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab versus placebo in adults with hypereosinophilic syndrome
2023-510346-25-00Phase 3Authorised
- Sponsor
- GSK
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in hypereosinophilic syndrome (HES) comparing Depemokimab arm with Placebo arm (2 arms). Primary endpoint: Frequency of HES flares during the 52-week study intervention period. Planned start Sep 2022; status: authorised.
02
Drugs
depemokimab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on 2023-510346-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510346-25-00.